ReviewDiscovery medicine2010
Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.
Review in Discovery medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Review
- Innate immune genes of the chicken MHC and related regions.Immunogenetics · 2022Review
- Genome-wide chromatin occupancy of BRDT and gene expression analysis suggest transcriptional partners and specific epigenetic landscapes that regulate gene expression during spermatogenesis.Molecular reproduction and development · 2021Article
- Identifying Crohn's disease signal from variome analysis.Genome medicine · 2019Article
- The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation.Acta pharmacologica Sinica · 2019Article
- BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.Journal of leukocyte biology · 2018Review
- Benefit of Apabetalone on Plasma Proteins in Renal Disease.Kidney international reports · 2018Article
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.Journal of medicinal chemistry · 2018Article
- Review
- BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Cellular and molecular life sciences : CMLS · 2017Review
- Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Knockout of BRD7 results in impaired spermatogenesis and male infertility.Scientific reports · 2016Article
- BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.PloS one · 2016Article
- Characterization of Genomic Variants Associated with Scout and Recruit Behavioral Castes in Honey Bees Using Whole-Genome Sequencing.PloS one · 2016Article
- Susceptibility Genes for Multiple Sclerosis Identified in a Gene-Based Genome-Wide Association Study.Journal of clinical neurology (Seoul, Korea) · 2015Article
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.Journal of medicinal chemistry · 2015Article
- BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.The Journal of biological chemistry · 2015Article
- H2A.Z: a molecular rheostat for transcriptional control.F1000prime reports · 2015Review
- BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes.European journal of immunology · 2015Article
- Chemical synthesis of the ATAD2 bromodomain.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Double bromodomain proteins bind to acetylated lysines in histones, bringing associated histone modification and nucleosome remodeling activity to chromatin. The ability of bromodomain regulators to alter chromatin status and control gene expression has long been appreciated to be important in the development of certain human cancers. However, bromodomain proteins have now been found also to be critical, non-redundant players in diverse, non-malignant phenotypes, directing transcriptional programs that control adipogenesis, energy metabolism and inflammation. The fact that such different processes are functionally linked by the same molecular machinery suggests a common epigenetic basis to understand and interpret the origins of several important co-morbidities, such as asthma or cancer that occurs in obesity, and complex inflammatory diseases like cardiovascular disease, systemic lupus erythematosus, rheumatoid arthritis and insulin resistance that may be built on a common pro-inflammatory foundation.
Indexed as
Identifiers
21189220PMC3025494W1579598701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.